271 related articles for article (PubMed ID: 23817592)
1. Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer.
Yoshii H; Ito K; Asano T; Horiguchi A; Hayakawa M; Asano T
Oncol Rep; 2013 Sep; 30(3):1073-80. PubMed ID: 23817592
[TBL] [Abstract][Full Text] [Related]
2. Dual role of TGFBR3 in bladder cancer.
Liu XL; Xiao K; Xue B; Yang D; Lei Z; Shan Y; Zhang HT
Oncol Rep; 2013 Sep; 30(3):1301-8. PubMed ID: 23835618
[TBL] [Abstract][Full Text] [Related]
3. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.
Behnsawy HM; Miyake H; Abdalla MA; Sayed MA; Ahmed Ael-F; Fujisawa M
Urol Oncol; 2011; 29(5):495-501. PubMed ID: 19914103
[TBL] [Abstract][Full Text] [Related]
4. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
5. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
[TBL] [Abstract][Full Text] [Related]
6. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma.
Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Salmas M; Malamou-Mitsi V
BJU Int; 2005 Mar; 95(4):655-9. PubMed ID: 15705098
[TBL] [Abstract][Full Text] [Related]
7. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Zhang Z; Zhang G; Kong C
Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
[TBL] [Abstract][Full Text] [Related]
8. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
9. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
10. Histological growth pattern of and alpha-actinin-4 expression in thyroid cancer.
Tanaka N; Yamashita T; Yamamoto S; Matsunobu T; Tsuda H; Honda K; Yamada T; Tamai S; Shiotani A
Anticancer Res; 2014 Jun; 34(6):3157-63. PubMed ID: 24922688
[TBL] [Abstract][Full Text] [Related]
11. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
12. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
13. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
14. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
[TBL] [Abstract][Full Text] [Related]
15. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection.
Muramaki M; Miyake H; Terakawa T; Kumano M; Sakai I; Fujisawa M
Urol Oncol; 2012; 30(2):161-6. PubMed ID: 20451421
[TBL] [Abstract][Full Text] [Related]
16. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
May M; Helke C; Nitzke T; Vogler H; Hoschke B
Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy.
Hassan JM; Cookson MS; Smith JA; Johnson DL; Chang SS
J Urol; 2004 Sep; 172(3):882-4. PubMed ID: 15310989
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
19. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
20. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]